 Adagio Therapeutics Inc NASDAQ: ADGI was up more than 75 on Monday after the biotech firm said Omicron was unlikely to be more resistant against its investigational monoclonal antibody, ADG20, despite a record number of mutations. Morgan Stanley raised its price target on ADGI The stock further got a boost as Morgan Stanley upgraded it ... The post Morgan Stanley: Omicron will benefit this relatively new biotech firm appeared first on Invezz. 